CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup

Background: Survival of metastatic colorectal cancer (mCRC) patients has improved, but mainly for trial patients. New predictive and prognostic biomarkers validated in the general mCRC population are needed. Caudal-type homeobox 2 (CDX2) is an intestine-specific transcription factor with potential p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Aasebø, Kristine, Dragomir, Anca, Sundström, Magnus, Mezheyeuski, Artur, Edqvist, Per-Henrik, Eide, Geir Egil, Ponten, Fredrik, Pfeiffer, Per, Glimelius, Bengt, Sorbye, Halfdan
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2020
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7026487/
https://ncbi.nlm.nih.gov/pubmed/32117703
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00008
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados